Showing Results for: “type 1 diabetes”

Results of NIDDK’s, Fuzzy Logic Automated Insulin Regulation (FLAIR) study showed increased time in range and improved A1C levels in adolescents and young adults who used system Medtronic’s Advanced Hybrid Closed-Loop system use in adolescents and young adults with type 1 diabetes (T1D) can lead to improved daytime blood sugar control without an increase in hypoglycemia, according to research presented today at the American Diabetes Association’s® (ADA’s) 80th Scientific Sessions. The presentation, “FLAIR—An NIDDK-Sponsored International, Multi-site Randomized Crossover Trial of AHCL vs. 670G

Results Demonstrate Enhanced Diabetes Management and Quality of Life with Advanced Technology New data focused on advanced technology innovations for managing type 2 diabetes (T2D) highlight the positive impact of automated insulin delivery systems (AID) and continuous glucose monitoring (CGM) in improving glycemic control and overall diabetes management. Three studies showing advancements for type 2 diabetes were presented at the American Diabetes Association’s ® (ADA) 84th Scientific Sessions in Orlando, FL. Of the nearly 40 million Americans with diabetes, more than 90% have type 2 diabetes

Largest-Study-of-its-Kind Uncovers Potential Underlying Condition for People with Difficult-to-Control Type 2 Diabetes and Need for Improved Screening and Treatment Approaches Today, findings from the CATALYST study reveal that hypercortisolism may be a significant factor for why type 2 diabetes (T2D) remains difficult to control for many patients. This study found that 24% of individuals with difficult-to-control type 2 diabetes have hypercortisolism, a condition characterized by high cortisol levels. The results were presented as a late-breaking symposium today at the 84th Scientific

The U.S. Food and Drug Administration (FDA) convened the Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC) on May 27, 2021, to review Teplizumab, which has shown the ability to delay the onset of Type 1 diabetes symptoms by two years. The American Diabetes Association ® (ADA) applauds the FDA Advisory Committee’s approval of Teplizumab for those at risk for developing type 1 diabetes (T1D). Click here to view the official comments submitted by the ADA. In response, Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA shared the following: “This is undoubtedly

I was 13 months old when I was diagnosed with T1D and I was diagnosed on my dad’s birthday! My parents were out getting some frosties from Wendy’s and they say that I kept reaching for them because I was thirsty. Well, later on I kept wetting my diaper. My dad would come in and change me, then he would come back in 10 minutes and have to do it again. This happened 3 times and they finally decided to take me in and see what was wrong. Turns out that their new baby was a type 1 diabetic. Surprise! I had a great team taking care of me in Montana when I was a baby and my mother (who just recently

Update on SCORED and SOLOIST trials shows reduction in cardiovascular events and stroke using glucose-lowering agents Results from two large clinical trials show significant and early benefits from sotagliflozin, a drug that inhibits sodium-glucose transport protein 2 (SGLT2) and sodium-glucose transport protein 1 (SGLT1) in reducing heart failure, heart attack, and stroke—major problems in people with diabetes. The findings were presented at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Patients with diabetes are at an increased risk of life-threatening

Results of the PIONEER 6 trial indicate oral semaglutide is safe for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk, according to results announced at the symposium titled “Oral Semaglutide—The PIONEER Program Trials” today at the American Diabetes Association’s® (ADA) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Oral semaglutide reduced cardiovascular death and all-cause mortality by nearly 50 percent, based on median follow up of 15.9 months. PIONEER 6 was conducted across 21 countries and included 3,183 participants who were randomized

American Diabetes Association Symposium Showcases New Potential Solution for Patients at High-Risk of Kidney Outcomes Today, findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 (glucagon-like peptide-1) receptor agonist were reported, demonstrating semaglutide significantly reduces the risk of major kidney disease events and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. New data presented here also highlighted the likely benefits of combined therapy with SGLT2 inhibitors. The results were presented at a symposium

Danielle has been living with type 2 diabetes for seven years. She’s written two books to empower and educate others living with diabetes. This is her story: Hello, my name is Danielle, and I'm a type 2 diabetic. I was first diagnosed back in 2013, and I instantly went into denial because I could not believe I was a diabetic. I instantly stereotyped what and who I should be as someone with diabetes. I was in denial for a very long time, but when my first symptom showed up, I took control of my life and became a fighting machine against this disease. I became an author with my first book, Let

Ella's diagnosis came as a shock to Noelle, her mother. Now, Noelle is committed to educating others about the warning signs of type 1 diabetes. This is Noelle's story: Ella was brought to the doctor when she was 22 months old, when I was concerned about her weight loss and constant peeing through diapers. We were told it was a urinary tract infection (UTI) and sent on our way. Luckily, mama's intuition was a bit stronger and I pushed for a urine test. Just 24 hours later, we were in the pediatric intensive care unit in diabetic ketoacidosis (DKA), and left with a new type 1 diabetes diagnosis